An earlier paradigm shift occurred with the discovery that monoclonal antibodies directed against the cytokine TNFα achieved remarkable success in the treatment of patients with IBD [54,55], suggesting that IBD was a result in part of dysregulated immunomodulatory mechanisms. This evidence concerns the gene TNF and inflammatory bowel disease.